Global Central Nervous System (CNS) Therapeutics Market Size, Share, Growth & Report 2023-2028

Byimarcsuraj

IMARC Group has recently released a new research study “Central nervous system (CNS) therapeutics Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028”, offers a detailed analysis of the market drivers, segmentation, growth opportunities, trends, and competitive landscape to understand the current and future market scenarios.

What Are The Growth Prospects Of The Central Nervous System (CNS) Therapeutics Industry?

The global central nervous system (CNS) therapeutics market size reached US$ 131.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach a value of US$ 214.6 Billion by 2028, exhibiting a growth rate (CAGR) of  6.8% during 2023-2028.

What Is A Central Nervous System (CNS) Therapeutics?

The central nervous system (CNS) represents a vital part of the nervous system that consists of the brain and the spinal cord. It incorporates the received information, thereafter, controlling and coordinating the activities of all aspects of the body. However, various CNS disorders, such as neurodegenerative diseases, autoimmune and inflammatory illnesses, genetic disorders, cancers, and others, affect the structure and function of the brain or spinal cord. Thus, CNS therapeutics are used to treat these disorders. These medications include sedatives, tranquilizers, and hypnotics that can slow brain activity, making them useful for treating panic, acute stress reactions, anxiety, and sleep disorders in individuals.

Request For Sample Report: https://www.imarcgroup.com/central nervous system (CNS) therapeutics-market/requestsample

What Are The Key Factors Driving In The Central Nervous System (CNS) Therapeutics Market?

The rising approval of generic products, owing to patent expiration of essential medicines, such as Copaxone and Invega, has led to an expansion in treatment rate, especially in low- and middle-income countries, which is among the primary factors driving the central nervous system (CNS) therapeutics market. Besides this, the launch of several policies by the government bodies to boost the number of clinical trials and the introduction of innovative medications with improved efficacy, dosage, formulation, and aftereffects are further augmenting the market growth.

Moreover, the growing popularity of transdermal patches for central nervous system disorders that provide a precise amount of medicine and relief is also catalyzing the global market. Apart from this, the increasing advancements in the drug-delivery systems that have an edge over conventional methods, on account of the reduced adverse effects, are acting as significant growth-inducing factors. Furthermore, the elevating focus of the leading pharmaceutical players toward new therapies to prevent or enhance the symptoms of neurological disorders is expected to bolster the central nervous system (CNS) therapeutics market in the coming years.     

Who Are The Key Players/Companies In Central nervous system (CNS) therapeutics Market?

AstraZeneca plc, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG (Roche Holding), H. Lundbeck A/S, Merck & Co. Inc., Neurocrine Biosciences Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited and Teva Pharmaceutical Industries Ltd.

Report Segmentation:

The report has been segmented the market into following categories:

Breakup by Disease:

  • Neurodegenerative Diseases
    • Alzheimer’s Disease
    • Parkinson’s Disease
    • Multiple Sclerosis
    • Huntington’s Disease
    • Amyotrophic Lateral Sclerosis
    • Others
  • Neurovascular Diseases
  • CNS Trauma
  • Mental Health
    • Anxiety Disorders
    • Epilepsy
    • Mood Disorders
    • Psychotic Disorders
    • Others
  • Infectious Diseases
  • CNS Cancer
  • Others

Breakup by Application:

  • Hospital 
  • Clinic 
  • Homecare 
  • Others

By Geography

  • North America (United States, Canada)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Others)
  • Asia Pacific (China, Japan, India, Australia, Indonesia, Korea, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa (United Arab Emirates, Saudi Arabia, Qatar, Iraq, Other)

Ask An Analyst: https://www.imarcgroup.com/request?type=report&id=6114&flag=C

About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Services Private Limited.

30 N Gould St Ste R Sheridan, WY 82801

USA – Wyoming

Email: Sales@imarcgroup.com

Tel No:(D) +91 120 433 0800

Americas:- +1 631 791 1145 |

Africa and Europe :- +44-702-409-7331 |

 Asia: +91-120-433-0800, +91-120-433-0800